Spots Global Cancer Trial Database for Safety and Efficacy Evaluation of CD19-UCART
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Evaluation of CD19-UCART
Official Title: A Safety and Efficacy Study of CD19-UCART (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor) in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Study ID: NCT03229876
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
Detailed Description: CD19-UCART is a kind of "off-the-shelf" product originated from health donor's PBMC.This is a open-label, dose estilation study to evaluate the safety and anti-tumor efficacy of CD19-UCART in the treatment of relapsed or refractory B-cell hematological malignancies.
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Affliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
First Affliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Yi Zhang, Professor
Affiliation: First Affliated Hospital of Zhengzhou University
Role: PRINCIPAL_INVESTIGATOR
Name: He Huang, Professor
Affiliation: First Affliated Hospital of Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
